Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues  by Dusserre, Eric et al.
Di¡erences in mRNA expression of the proteins secreted by the
adipocytes in human subcutaneous and visceral adipose tissues
Eric Dusserre a;b, Philippe Moulin b, Hubert Vidal a;*
a INSERM U449 and GENALYS, Faculte¤ de Me¤decine R.T.H. Lae«nnec, F-69373 Lyon Cedex 08, France
b Laboratoire de Me¤tabolisme des Lipides, Ho“pital de l’Antiquaille, Lyon, France
Received 20 April 1999; received in revised form 23 July 1999; accepted 24 August 1999
Abstract
We have investigated the difference in gene expression of six proteins secreted by adipocytes in paired biopsies from
visceral and abdominal subcutaneous adipose tissue in nine individuals with various degrees of obesity. The mRNAs levels of
leptin, TNFK, angiotensinogen, acylation stimulating protein (ASP), cholesterol ester transfer protein (CETP) and
phospholipid transfer protein (PLTP) were quantified by RT-competitive PCR. ASP and angiotensinogen mRNA levels were
higher in the visceral fat, whereas the mRNA levels of leptin and CETP were higher in the subcutaneous depot. TNFK
mRNA expression was similar in the two sites. For angiotensinogen, the difference was more pronounced in the subjects with
body mass index (BMI) lower than 30 kg/m2 whereas for ASP, CETP and leptin, the difference was observed regardless the
BMI of the subjects. PLTP mRNA levels in subcutaneous, but not in the visceral, adipose tissue were positively related to the
BMI of the subjects. These results strongly suggest that visceral and subcutaneous adipocytes may have different properties
in the production of bioactive molecules. ß 2000 Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Subjects with accumulation of visceral fat are at a
higher risk for the development of obesity-related
metabolic derangements, such as type-2 diabetes, car-
diovascular disease, hypertension and hyperlipidemia
[1^3]. The molecular basis of this association between
intra-abdominal obesity and health problems is still
largely unknown. Di¡erent properties between adi-
pocytes from the intra-abdominal or the subcutane-
ous depots have been reported, especially regarding
the control of lipolysis [4,5]. In addition, because
adipocytes are now regarded as endocrine-like cells,
capable of secreting several molecules and hormones
[6,7], depot-related di¡erences in the production of
some of them could participate in the disorders
linked to visceral obesity. This concept was recently
reenforced with the demonstration that visceral adi-
pocytes express and produce more plasminogen-acti-
vator inhibitor 1 (PAI-1) than subcutaneous cells
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[8,9]. Among the numerous adipocyte-derived prod-
ucts identi¢ed so far, some play a role in the regu-
lation of the fat mass and the control of adipocyte
di¡erentiation [6,7,10]. Others are involved in the
control of lipid and cholesterol metabolisms [11,12].
Some of them also participate in the immune system
[13,14] and in the regulation of the blood £ow and
vascular functions [15^17]. With regard to their mul-
tiple biological functions, it is likely that they partic-
ipate in the metabolic consequences of obesity, such
as altered lipid metabolism, insulin resistance and
cardiovascular complications. It is therefore impor-
tant to verify whether adipose tissue depot-speci¢c
di¡erences exist in the expression and production
of these factors in humans.
In the present study, we have evaluated the gene
expression of several of these proteins in paired
omental and abdominal subcutaneous adipose tissue
biopsies from subjects spanning a wide range of body
mass index (BMI). Due to the small size of the tissue
samples and to the very low yields in total RNA
from adipose tissue, we have elaborated a multispe-
ci¢c competitor cDNA construct for the quanti¢ca-
tion by reverse transcription-competitive polymerase
chain reaction (RT-cPCR) assay [18] of mRNAs en-
coding adipocyte-secreted proteins. We have investi-
gated the fat depot-related di¡erence in mRNA ex-
pression of acylation stimulating protein (ASP),
cholesterol ester transfer protein (CETP) and phos-
pholipid transfer protein (PLTP), three major deter-
minants of lipid and lipoprotein metabolism, leptin
and tumor necrosis factor K (TNFK), two cytokines
that participate in the control of the fat mass and
potentially in the development of insulin-resistance,
and angiotensinogen, a possible contributor to the
obesity-related cardiovascular risk.
2. Materials and methods
2.1. Subjects and tissue sampling
Abdominal subcutaneous and visceral (omental)
adipose tissue biopsies were obtained from nine pa-
tients (¢ve women, four men) during elective open
abdominal surgery. Patients with a previous history
of coronary heart disease (angina pectoris or myo-
cardial infarction) were excluded from the study.
None of the subjects su¡ered from severe systemic
illness, diabetes mellitus or other diseases known to
interfere with lipid metabolism. Their age ranged
from 30 to 66 years (mean þ S.E.M. = 42 þ 5 years)
and all had a stable body weight for at least 3 months
(BMI ranging from 18 to 58 kg/m2, mean = 34 þ 4 kg/
m2). Tissue samples were immediately frozen in
liquid nitrogen and stored at 380‡C until total
RNA preparation. All patients gave their written in-
formed consent, and the project was approved by the
ethics committee of Hospice Civil de Lyon.
2.2. Total RNA preparation and target mRNA
quanti¢cation
Adipose tissue total RNA was prepared using the
RNeasy total RNA kit (Qiagen, Courtaboeuf,
France). RNA samples were quanti¢ed by spectro-
photometry and the absorption ratios at 260 to at
280 nm were between 1.8 and 2.0. Average yields
were similar in samples from subcutaneous
(1.2 þ 0.2 Wg of total RNA/100 mg of tissue) and
omental adipose tissue (1.4 þ 0.2 Wg/100 mg of tis-
sue). Total RNA samples were diluted in water and
stored at 380‡C until use.
The concentration of the di¡erent mRNAs was
determined by an RT-cPCR assay that consists, after
a speci¢c reverse transcription reaction, of the co-
ampli¢cation of the target single-strand cDNA with
known amounts of a DNA competitor molecule
added in the same PCR tube [18]. We have developed
a multispeci¢c competitor DNA to quantify the lev-
els of the mRNAs encoding ASP, CETP, PLTP,
LPL, angiotensinogen, PAI-1, leptin, TNFK and
L-actin (see after for details of the construction).
For the assay of the target mRNAs, speci¢c reverse
transcription reactions were performed from 0.1 or
0.2 Wg of tissue total RNA with 2.5 U of thermo-
stable reverse transcriptase (Tth, Promega, Charbo-
nie'res, France) and in the presence of 15 pmol of one
of the speci¢c antisense primer. The conditions re-
quired to obtain the transformation of all the target
mRNA molecules into single strand cDNA during
the reverse transcription reaction have been de-
scribed in detail previously [18]. For cPCR ampli¢-
cation, the reverse transcription medium was added
to a PCR master mix (10 mM Tris-HCl pH 8.3,
100 mM KCl, 0.75 mM EGTA, 5% glycerol) con-
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taining 0.2 mM deoxynucleoside triphosphates, 5 U
of Taq polymerase (Life Technologies, Cergy Pon-
toise, France), 30 pmol of the speci¢c antisense prim-
er and 45 pmol of the speci¢c sense primer. The
sense primers were 5P-labelled with the CY-5 £uores-
cent dye (Eurogentec, Seraing, Belgium). The ¢nal
volume was 100 Wl and four aliquots of 20 Wl were
transferred to 0.5-ml microtubes containing 5 Wl of a
de¢ned working solution of the DNA competitor.
After 120 s at 94‡C, the PCR mixtures were sub-
jected to 40 cycles of PCR ampli¢cation with a cycle
pro¢le including denaturation for 60 s at 94‡C, hy-
bridization for 60 s at 58‡C and elongation for 60 s
at 72‡C. The PCR products were separated and an-
alyzed in 4% polyacrylamide gel electrophoresis (6%
for CETP mRNA assay) on a ALFexpress DNA
sequencer (Pharmacia, Upsala, Sweden) using the
Fragment Manager software (Pharmacia) [19]. The
concentration of the target mRNAs was determined
at the competition equivalence point as described in
detail previously [18]. The absence of contamination
with genomic DNA was checked by omitting reverse
transcriptase in the reaction. To ensure that the dif-
ference in mRNA levels between paired subcutane-
ous and visceral adipose tissue samples were not due
to subtle methodological di¡erences, total RNA were
always prepared simultaneously from the two biop-
sies of the same subject and target mRNAs were
measured in the same run of PCR, with the same
dilutions of competitor.
2.3. Construction of the competitor
Fig. 1 depicted the organization of the homolo-
gous multispeci¢c competitor DNA (as de¢ned in
[18]) that was used to quantify the target mRNAs.
First, we have constructed the nine speci¢c compet-
itors individually. A cDNA fragment of each target
mRNA was obtained by RT-PCR from human adi-
pose tissue using the speci¢c sense and antisense
primers (Table 1) and high-¢delity pfu DNA poly-
merase (Stratagen, La Jolla, CA). Each fragment
was subcloned (pGEM-T Vector System, Promega)
and used to generate a speci¢c competitor either by
restriction enzyme digestion and ligation (for ASP,
PLTP, LPL, leptin, TNFK and L-actin) or by a
PCR-based deletion/mutagenesis method [20] (for
CETP, angiotensinogen and PAI-1). Each competi-
tor gave rise to a PCR product that was slightly
shorter in size than the normal cDNA (Table 1).
To generate the complete molecule, individual com-
petitor cDNAs were associated together (lep-
tin+LPL, CETP+ASP+angiotensinogen, PLTP+L-
actin+TNFK, PAI-1) using a PCR overlap extension
method [20] and high-¢delity pfu DNA polymerase.
The four fragments were then subcloned successively
in the same plasmid (pGEM) to obtain the full
length (2969 bp) multispeci¢c homologous competi-
tor (Fig. 1). Its sequence, veri¢ed by automatic DNA
sequencing, matched perfectly the target mRNA se-
quences reported in GenBank. The plasmid was fur-
ther puri¢ed, carefully quanti¢ed and stored at
320‡C. Working solutions of the competitor plasmid
(20 amol/Wl to 1033 amol/Wl) were prepared by serial
dilutions in 10 mM Tris-HCl (pH 8.3), 1 mM EDTA
bu¡er.
To validate the assays, nine RNAs corresponding
to part of the target mRNAs were synthetised by in
vitro transcription (Riboprobe system, Promega) us-
ing the plasmids containing the cDNA fragments in-
itially obtained by RT-PCR and subcloned in pGEM
(see before). Known amounts of these RNAs (0.1^50
amol added into the RT medium) were measured by
RT-cPCR to generate dose^response curves that
were all linear demonstrating that the assays were
really quantitative. The coe⁄cient of variation of
the di¡erent assays was between 9 and 18% when a
given mRNA was measured several times in the same
tissue sample. The validations of the RT-cPCR-based
assays have been reported in detail in a methodolog-
ical paper [18].
2.4. Presentation of the results
Absolute mRNA levels were determined and pre-
sented as amol/Wg of total RNA. Data are shown as
means þ S.E.M. Because we have previously exam-
ined the expression of LPL in the two fat depots
[21], we did not measured LPL mRNA in the present
study. Moreover, due to the low amounts of total
RNA obtained with some biopsies and because de-
pot-related di¡erence in its expression has been al-
ready reported [8,9], we also did not investigate the
expression of PAI-1 mRNA in this study. The di¡er-
ences between omental and subcutaneous mRNA
levels were compared using a non-parametric Wil-
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coxon test for paired values. The correlations be-
tween BMI and mRNA levels (or mRNA level ratio)
were examined using the non-parametric Spearman’s
rank correlation coe⁄cient. The threshold for signi¢-
cance was set at P6 0.05.
3. Results
The sequences of the di¡erent primers used for the
RT-cPCR and the sizes of the target and competitor
PCR products that are generated during the reac-
tions are presented in Table 1. All the target mRNAs
can be properly ampli¢ed from 0.1 or 0.2 Wg of total
RNA from human adipose tissue (data not shown).
Fig. 2 shows the absolute mRNA levels (expressed as
amol/Wg of total RNA) determined in abdominal
subcutaneous and visceral fat depots. Large di¡er-
ences in the expression levels of the target mRNAs
were observed in human adipose tissue. ASP mRNA
was abundantly expressed, PLTP and leptin mRNAs
were at intermediary levels whereas CETP, angioten-
sinogen and TNFK transcripts were expressed at
extremely low levels (Fig. 2). The mRNA encoding
L-actin was measured to verify the integrity of the
total RNA preparations. As compared with the other
mRNAs of interest, L-actin was expressed at high
levels both in subcutaneous and visceral fat.
The mRNA levels of ASP and angiotensinogen
were signi¢cantly higher in the visceral adipose tissue
(P = 0.03 for ASP and P = 0.01 for angiotensinogen
mRNA, respectively). On the opposite, leptin
(P = 0.02) and CETP (P = 0.01) mRNAs were more
expressed in the subcutaneous adipose tissue (Fig. 2).
The average values of PLTP and TNFK mRNA lev-
els were similar in subcutaneous and in visceral adi-
pose tissue (Fig. 2). Because of the low number of
subjects, and to ensure that the di¡erences were real
and not due to chance ¢ndings, we determined the
statistical power of the analyses. We found values
higher than 80% for leptin, CETP and angiotensino-
gen and of 65% for ASP, indicating thus that the
results likely correspond to real di¡erences. For
ASP, leptin and CETP mRNAs, the depot-related
di¡erence was found in almost all subjects, regardless
of their BMI (Fig. 3). For angiotensinogen mRNA, a
Fig. 1. Organization of the multispeci¢c competitor. The nine homologous competitors were constructed individually and cloned in
the pGEM plasmid vector to generate the full length (2969 bp) multispeci¢c competitor, as described in Section 2. The arrows indicate
the position and orientation of the sense (S) and antisense (AS) primers for each target (see Table 1 for their sequences). The number
of nucleotides that was deleted from the normal cDNA sequences is indicated in brackets.
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marked depot-related di¡erence was found in the
four subjects with BMI lower than 30 kg/m2. These
latter had an about 4-fold higher level of angiotensi-
nogen mRNA in the visceral as compared to the
subcutaneous fat depot (Fig. 3). Regarding PLTP
mRNA expression, there was no depot-related di¡er-
ence when the mean level values were considered
(Fig. 2). However, there was a negative correlation
between the visceral to subcutaneous ratio of PLTP
mRNA and the BMI of the subjects (Fig. 3). Finally,
there was no depot-related di¡erence in the mRNA
levels of TNFK, either in lean or in obese subjects
(Figs. 2 and 3).
We further analyzed the possible relationships be-
tween the target mRNA expression levels in the two
fat depots and the degree of obesity of the subjects
(Table 2). Leptin mRNA levels were positively corre-
lated with the BMI of the subjects both in the sub-
cutaneous and the visceral depots. Similar results
were found with TNFK mRNA levels. Angiotensino-
gen mRNA levels correlated positively with the BMI
in the subcutaneous but not in the visceral adipose
tissue. Similarly, a signi¢cant positive correlation was
found between PLTP mRNA levels and the BMI in
the subcutaneous but not in the visceral depot. In-
terestingly, PLTP mRNA levels in the subcutaneous
adipose tissue was also associated with the waist to
hip circumference ratio of the subjects (r = 0.956,
Table 1
Sequences of the primers used for the RT-cPCR assays





12115P-TTCTGCACACCGAGCTGAAC-3P1230 14895P-TTGCCAGGCACTGTGTTCTG-3P1470 281 261
ASP (K02765) 1765P-TCCTGGACTGCTGCAACTAC-3P195 4175P-AATCTCCCACGTGGTGATGG-3P398 244 229
CETP (M30185) 10305P-AAGATGCCCAAGATCTCCTG-3P1049 14755P-AAGCTCTGGAGGAAATCCAC-3P1456 448 428
Leptin (U43653) 15P-ATGCATTGGGGAACCCTGTGCGG-3P23 4855P-AGGTCCAGCTGCCACAGCATGTC-3P463 487 407
LPL (M15856) 6525P-GGTCGAAGCATTGGAATCCAG-3P672 10135P-TAGGGCATCTGAGAACGAGTC-3P993 364 310
PAI-1 (M16006) 15P-ATGCAGATGTCTCCAGCCCTCAC-3P23 4725P-TGAATCTGGCTCTCTCCACCTC-3P451 472 406
PLTP (L26232) 3155P-GCTCTACTGGTTCTTCTATG-3P334 6475P-TCAATGCCAACAAGCTCGTC-3P628 335 290
TNFK (X01394) 2615P-GCCTGTAGCCCATGTTGTAG-3P280 5185P-ATGGCAGAGAGGAGGTTGAC-3P499 260 228
L-Actin (X00351) 3385P-AGGCCAACCGCGAGAAGATGAC-3P359 7255P-AGCTCGTAGCTCTTCTCCAGGG-3P704 390 318
The location of the primers on the coding sequences of the target mRNAs is indicated by indexed numbers. The GenBank accession
numbers of the nine targets are indicated in brackets. The target mRNAs and the competitors generated PCR products of di¡erent
sizes allowing their separation on polyacrylamide gel electrophoresis. The sense primers were 5P-end labeled with the £uorescent dye
CY-5 for analysis on an automated £uorescence DNA sequencer.
Fig. 2. Expression levels of the target mRNA in the subcutaneous and in the visceral adipose tissue. The absolute levels of the target
mRNAs were determined by RT-cPCR as described in Section 2 in paired adipose tissue biopsies from abdominal subcutaneous (open
boxes) and visceral (hatched boxes) fat depots. *P6 0.05, n = 9 subjects.
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P = 0.011). None of the other target mRNA levels
was correlated with this parameter.
Despite a tendency for leptin (r = 0.666, P = 0.08)
and for TNFK (r = 0.633, P = 0.07) mRNAs, there
was no signi¢cant correlation between the mRNA
levels in the subcutaneous fat and the mRNA levels
in the visceral adipose tissue for any of the target
genes.
4. Discussion
To investigate whether the gene expression of im-
portant proteins secreted by adipocytes di¡ers be-
tween visceral and subcutaneous human adipose tis-
sue depots, the mRNAs levels of ASP, PLTP, leptin,
CETP, TNFK and angiotensinogen were quanti¢ed
by RT-cPCR in paired biopsies from individuals with
various degrees of obesity. In agreement with pre-
vious reports, leptin mRNA was found to be more
expressed in subcutaneous than in omental fat [21^
23]. We also con¢rmed the lack of depot-related dif-
ference in the mRNA expression of TNFK in human
adipose tissue [24]. On the other hand, our study
demonstrated, for the ¢rst time, that mRNA expres-
sions of ASP, angiotensinogen, CETP and PLTP are
di¡erent in intra-abdominal compared to subcutane-
ous adipose tissues in humans.
Depot-related di¡erences in the metabolic func-
tions of adipocytes have already been reported and
suggested to participate in the link between visceral
fat accumulation and a higher risk for cardiovascular
disease and other obesity-related outcomes [1]. Vis-
ceral adipocytes are less responsive to the anti-li-
polytic action of insulin and more responsive to the
lipolytic action of catecholamines [4,5]. These meta-
bolic di¡erences are not related to di¡erences in the
expression levels of the genes coding either key en-
zymes of triacylglycerol hydrolysis [21,24] or the
main steps of insulin action [21]. Therefore, the in-
creased lipolytic rates of omental adipocytes are most
Fig. 3. Relationship between BMI and the relative mRNA levels of the target genes in visceral versus subcutaneous adipose tissue
biopsies.
Table 2
Spearman correlation coe⁄cients for the relationships between
target mRNA levels and the BMI of the subjects in the subcu-





b P b P
L-actin 0.300 0.396 0.567 0.109
ASP 0.550 0.120 30.017 0.962
PLTP 0.733 0.038 30.177 0.637
Leptin 0.673 0.048 0.644 0.049
CETP 0.159 0.652 30.200 0.572
TNFK 0.903 0.011 0.753 0.034
Angiotensinogen 0.837 0.018 30.132 0.706
BBADIS 61894 28-10-99
E. Dusserre et al. / Biochimica et Biophysica Acta 1500 (2000) 88^96 93
probably due to di¡erences in the hormonal control
of the metabolic pathway, as previously discussed
[21]. In addition to this metabolic aspect, adipocytes
are now known to secrete several bioactive molecules
that may be involved in lipid metabolism, cardiovas-
cular functions and insulin resistance [7^17,25].
Therefore, the ¢nding that some of these molecules
are expressed di¡erently in visceral and in subcuta-
neous adipose tissue sheds new additional light on
the possible molecular link between intra-abdominal
fat accumulation and obesity-related metabolic dis-
eases. However, because we reported data at the
mRNA levels only, further studies are now needed
to verify whether the protein levels and their secre-
tion rates are also di¡erent between fat depots.
TNFK produced by adipose tissue is regarded as a
possible mediator of insulin resistance [25] and its
expression is increased in subcutaneous adipose tis-
sue of obese subjects [26,27]. We found that the cor-
relation between TNFK mRNA levels and the BMI
of the subjects is also present in the visceral adipose
tissue. However, the expression levels of TNFK in
human fat tissues are extremely low ([24], this study),
and therefore the contribution of adipose tissue to
the circulating levels of TNFK is questionable. It
was recently demonstrated using arteriovenous bal-
ance technique that the subcutaneous adipose tissue
do not release measurable amount of TNFK protein
into the circulation in lean and in obese subjects [13].
Our data indicated that a greater contribution of the
visceral fat is unlikely because there is no di¡erence
in the expression of TNFK mRNA between visceral
and subcutaneous depots.
We found that angiotensinogen mRNA levels are
higher in visceral fat, particularly in individuals with
BMI lower than 30 kg/m2 in whom a more than 4-
fold di¡erence was observed between omental and
subcutaneous mRNA abundances. In the more obese
subjects, this di¡erence was less apparent, mainly due
to signi¢cantly increased expression of angiotensino-
gen in subcutaneous adipose tissue without a change
in its expression in the visceral fat. Angiotensinogen
is the precursor of angiotensin II, an important reg-
ulator of blood pressure and of salt and water bal-
ance. Interestingly, angiotensin II can also partici-
pate in the regulation of adipocyte di¡erentiation
[28]. The mRNA expression of angiotensinogen, as
well as of the enzymes required for its conversion
into angiotensin II, has been already reported in hu-
man adipose tissue [15,16]. Our study demonstrates
that there is an increased expression of angiotensino-
gen in abdominal subcutaneous adipose tissue in
obese subjects. The observed depot-related di¡erence
in angiotensinogen expression might therefore be of
importance in the regulation of adipogenesis and in
the development of diseases secondary to fat accu-
mulation, such as hypertension.
ASP has been proposed to be a major determinant
of the rate of triglyceride synthesis in adipocytes (see
[29] for review). ASP is a 77 amino-acid long peptide
derived from the third component of the complement
(C3a) by interactions of the proteins of the alterna-
tive complement pathway factor B, factor D and C3
[29]. These three proteins are all produced by adipo-
cytes [11,30]. Since ASP is generated by post-trans-
lational modi¢cation of the protein C3a (removal of
the carboxy-terminal arginine), the RT-cPCR assay
developed in the present work is speci¢c for the
mRNA encoding the fragment C3a of the C3 gene
[31]. Therefore, if the post-translational modi¢ca-
tions are limiting steps in the production of ASP,
the measured ASP/C3a mRNA levels might not esti-
mate correctly the expression of the ASP protein.
Nevertheless, our results showed that ASP/C3a
mRNA is expressed at very high levels in human
adipose tissue. The abundance of ASP/C3a mRNA
is about two-fold higher in visceral adipose tissue as
compared with abdominal subcutaneous fat. If this
di¡erence is re£ected at the protein level, a higher
local production of ASP in omental fat should result
in increased rates of fatty acid uptake and reesteri¢-
cation. However, this seems not to be the case since
omental adipocytes have been shown to be charac-
terized by a greater lipolytic rate and reduced respon-
siveness to insulin [4]. It may be possible that ASP/
C3a gene expression is increased in omental fat as a
compensatory phenomenon to counteract the greater
lipolytic capacity of the visceral cells.
Obesity, and predominantly intra-abdominal fat
accumulation, is usually associated with major ab-
normalities in lipoprotein pro¢le [1,3]. Movements
of neutral lipids and phospholipids between the dif-
ferent plasma lipoproteins involve the action of the
lipid transfer proteins CETP and PLTP (see [32] for
review). CETP mediates the net transfer of cholester-
ol ester and its exchange with triglycerides from
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HDL to VLDL, and PLTP possesses a phospholipid
transfer activity from VLDL to HDL as well as an
HDL conversion activity [32]. CETP mRNA expres-
sion has already been demonstrated in human adipo-
cytes and is related to the membrane cholesterol con-
tent of the cells [12]. In addition, a recent report
suggested that adipose tissue production may con-
tribute to the plasma concentration of CETP protein
[33]. Plasma CETP protein mass and activity are in-
creased in obese subjects [34] ; however, we did not
¢nd correlation between CETP mRNA expression in
adipose tissue and the BMI of the subjects. Subcuta-
neous adipose tissue level of CETP mRNA is about
two-fold higher than the expression in visceral fat,
regardless of the degree of obesity of the subjects.
Interestingly, subcutaneous adipocytes have been
shown to possess higher cholesterol content and
HDL binding capacities than omental fat cells [35].
The greater expression of CETP in subcutaneous adi-
pose tissue may therefore participate in this depot-
speci¢c di¡erence in cholesterol metabolism. Alterna-
tively, however, the di¡erence in cholesterol metabo-
lism in the two fat depots may in£uence the expres-
sion of CETP gene.
Contrary to CETP, PLTP expression has never
been reported in human adipose tissue. In this study,
we demonstrated that PLTP mRNA is actually ex-
pressed at relatively high level both in subcutaneous
and in visceral adipose tissue. The average PLTP
mRNA levels were similar to those found for leptin
mRNA in obese subjects. These results suggest thus
that adipose tissue may contribute to the plasma lev-
el of PLTP. In addition, a signi¢cant depot-related
di¡erence in PLTP mRNA expression was observed,
particularly in lean subjects. The greater expression
of PLTP mRNA observed in the visceral fat in lean
subjects was compensated, in obese subjects, by an
increased levels of PLTP mRNA in subcutaneous
adipose tissue. Recently, plasma PLTP activity has
been related to insulin resistance and to alterations in
HDL metabolism in obese type-2 diabetic patients
[36]. The same group has also demonstrated that
plasma PLTP activity was positively related to the
BMI, the waist to hip circumference ratio and fasting
blood glucose in obese non-diabetic men [37]. In view
of the high level of PLTP mRNA expression in hu-
man adipose tissue and of its correlations with the
BMI and the waist to hip ratio of the subjects, it will
be important to verify to which extent adipose tissue-
derived PLTP is involved in the regulation of HDL
metabolism and whether or not it plays a role in the
insulin resistance syndrome.
In summary, human adipose tissue presents signif-
icant depot-speci¢c di¡erences in the mRNA expres-
sion levels of several important proteins with bioac-
tive functions. Abdominal subcutaneous adipose
tissue displays a greater expression of leptin and
CETP mRNAs, whereas omental adipose tissue is
characterized by higher levels of ASP, angiotensino-
gen and PLTP mRNAs, particularly in subjects with
BMI lower than 30 kg/m2. It is now important to
verify whether the secretion rates of these factors
are also di¡erent between the fat depots in order to
de¢ne new molecular links between adipose tissue
distribution and the metabolic derangements associ-
ated with obesity.
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